



Published in final edited form as:

*Tetrahedron Lett.* 2010 July 7; 51(27): 3465–3469. doi:10.1016/j.tetlet.2010.04.077.

## The Conformations of 17 $\beta$ -Estradiol (E2) and 17 $\alpha$ -Estradiol as Determined by Solution NMR

Jianxin Guo, Richard I. Duclos Jr., V. Kiran Vemuri, and Alexandros Makriyannis\*

Center for Drug Discovery, Northeastern University, 360 Huntington Avenue, 116 Mugar Life Sciences Building, Boston, MA, 02115, USA

### Abstract

The conformational structures of the hormone 17 $\beta$ -estradiol (E2) and the epimeric 17 $\alpha$ -estradiol determined by solution NMR spectroscopy and restrained molecular dynamics calculations found a single low energy conformation.

### Keywords

17 $\beta$ -estradiol; E2; 17 $\alpha$ -estradiol; NMR; conformation; molecular modeling

### Introduction

Estrogens are gonadal steroidal hormones that have important roles in reproductive function.<sup>1,2</sup> These amphipathic steroids are quite insoluble in an aqueous environment,<sup>3,4</sup> but circulate via the bloodstream<sup>5</sup> signaling to a number of tissues including breast, ovaries, uterus, and brain.<sup>6</sup> Estrogens initiate rapid nongenomic signaling events at cell membranes,<sup>2,7-10</sup> readily diffuse across membranes interacting with nuclear estrogen receptors that regulate gene expression,<sup>6,11,12</sup> and also act at mitochondrial membranes.<sup>13</sup> Estrogen receptors are activated by the hormone 17 $\beta$ -estradiol (E2) but not by the 17 $\alpha$ -estradiol isomer (Figure 1).<sup>14,15</sup> Recently, the structure of the estrogen hormone 17 $\beta$ -estradiol (E2) as determined by NMR and X-ray was reviewed.<sup>16</sup> In addition to the low energy C-ring chair conformation that corresponded well to crystal structures, a second conformation with a twisted boat C-ring was proposed for E2 in dimethylsulfoxide solution.<sup>16</sup>

In conjunction with our ongoing studies of steroids interacting with phospholipid bilayer model membranes,<sup>17,18</sup> we have also characterized the solution structures of 17 $\beta$ -estradiol (E2) as well as 17 $\alpha$ -estradiol by NMR and restrained molecular dynamics calculations. Our data clearly demonstrate that for both E2 and the anomeric antiestrogen 17 $\alpha$ -estradiol, there is only one conformation that exists in solution.

\* To whom correspondence should be addressed: Center for Drug Discovery, Northeastern University, 360 Huntington Avenue, 116 Mugar Life Sciences Building, Boston, MA, 02115, USA. Tel: +1-617-373-4200; Fax: +1-617-373-7493; a.makriyannis@neu.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Results and discussion

We first assigned the proton resonances of 17 $\beta$ -estradiol (E2) as well as 17 $\alpha$ -estradiol by analysis of their 1D  $^1\text{H}$ -,  $^{13}\text{C}$ -, and 2D COSY, HSQC, and NOESY spectra recorded on a Bruker AVANCEII 700MHz NMR spectrometer (see supplementary data). All spectra were referenced to the DMSO- $d_6$  multiplets at 2.47 ppm and 39.50 ppm. The 2D HSQC experiment was particularly useful for distinguishing resonances of H $_{11\beta}$ , H $_8$ , H $_{15\beta}$  and H $_{7\alpha}$  for E2 that were between 1.19 and 1.27 ppm (see Figure 2). We have also, for the first time, distinguished the two benzylic geminal 6 $\alpha$  and 6 $\beta$  protons by analyzing the  $J$  couplings of this rather complicated ABXY pattern. Our analysis was further confirmed by comparing the  $^1\text{H}$ - spectrum of E2-6 $\beta$ - $d$  (Figure 3) which was synthesized in our lab according to a previously reported procedure.<sup>19</sup>

The observed proton chemical shifts, carbon chemical shifts, and the NOE intensities of key crosspeaks are tabulated for E2 and 17 $\alpha$ -estradiol in Tables 1 and 2, respectively. Their observed  $J$ -couplings are listed in Table 3. Strong trans coplanar diaxial couplings were observed for  $J_{6\beta,7\alpha}$ ,  $J_{7\alpha,8}$ ,  $J_{8,9}$ ,  $J_{8,14}$ ,  $J_{9,11\beta}$ ,  $J_{11\beta,12\alpha}$ , and  $J_{14,15\beta}$ . The chair conformation of the C-ring was clearly evidenced by the characteristic large  $J_{8,9}$ ,  $J_{8,14}$ ,  $J_{9,11\beta}$ , and  $J_{11\beta,12\alpha}$  couplings. The C-18 methyl group gave NOEs with H $_8$ , H $_{11\beta}$ , H $_{12\beta}$ , H $_{15\beta}$  and H $_{16\beta}$  for both 17 $\beta$ -estradiol (E2) and 17 $\alpha$ -estradiol, and NOE of the C-18 methyl with H $_{17}$  for 17 $\alpha$ -estradiol was also observed (Figure 4). We did not, however, observe the reported<sup>16</sup> NOE between H $_{12\beta}$  and H $_{15\beta}$  for E2 which was due to their mis-assignment of the proton resonances. Interestingly, the NOESY of H $_1$  with H $_{11\alpha}$  in the plane of the aromatic ring gave a negative NOE, an unusual effect.<sup>20,21</sup> This aromatic H $_1$  proton had the expected positive NOEs with H $_9$  and H $_{11\beta}$ , below and above the plane, analogous to H $_4$  NOEs with H $_{6\alpha}$  and H $_{6\beta}$ .

Our NOE data in Tables 1 and 2 were used as distance restraints to determine the conformations of 17 $\beta$ -estradiol (E2) and 17 $\alpha$ -estradiol, respectively. The calculations were performed using MacroModel in the Schrodinger software package. In order to fully sample the entire conformational space, stochastic dynamics simulations with NOE distance restraints were carried out at 1000K with a time step of 1.0 fs. Conformations were recorded every 250,000 steps for a total of 20 trajectories. Each conformer was further subject to conjugate gradient minimization until the maximum derivative was less than 0.05 kJ/mol. Figure 5a depicts the 20 conformers of 17 $\beta$ -estradiol (E2) and Figure 5b depicts the 20 conformers of 17 $\alpha$ -estradiol. For each compound, all 20 conformers were closely superimposable over the entire backbone. The solution conformations of the anomeric steroids were in good agreement with reported X-ray structures<sup>22-26</sup> and included the following features. The aromatic A-ring was planar. The unsaturated B-ring had trans coplanar diaxial orientations for H $_{6\beta}$  with H $_{7\alpha}$  and for H $_8$  with H $_9$  and was a half-chair (Figure 5c). The C-ring was a chair conformation with trans coplanar diaxial orientations for H $_{11\beta}$  with H $_9$  and H $_{12\alpha}$  as well as for H $_8$  with H $_9$  and H $_{14}$  (Figure 5d). Thus, the conformations of the ABC rings of both anomers were nearly identical. The five-membered D-rings were both C-13  $\beta$ -envelopes with only 3 $^\circ$  of distortion (C18-C13-C17 was 110.3 $^\circ$  for E2 and 107.3 $^\circ$  for the  $\alpha$ -anomer, Figures 5e and 5f, respectively) due to the steric interaction between the C-18 methyl group and the C-17 hydroxyl group of E2.

The conformational structures of the hormone 17 $\beta$ -estradiol (E2) and the anomeric antiestrogen 17 $\alpha$ -estradiol have now been clearly established in DMSO solution using a combination of NMR spectroscopy and restrained molecular dynamics calculations. We have found that there is only one low energy conformation for these steroids with a chair conformation for their C-rings. We have also, for the first time, assigned all resonances including the two benzylic geminal H $_{6\alpha}$  and H $_{6\beta}$  protons. We are currently using these

structural details to study the interactions of these compounds with bicelle model membranes.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


This work was supported by grants DA-152, DA-3801, DA-7215, DA-9158, and DA-24842 from the National Institute on Drug Abuse.

## References


1. Carrer HF, Cambiasso MJ. *Cell Mol Neurobiol.* 2002; 22:479. [PubMed: 12585676]
2. Micevych P, Kuo J, Christensen A. *J Neuroendocrinol.* 2009; 21:249. [PubMed: 19207814]
3. Hurwitz AR, Liu ST. *J Pharm Sci.* 1977; 66:624. [PubMed: 17710]
4. Iardia-Arana D, Kristensen HG, Mullertz A. *J Pharm Sci.* 2006; 95:248. [PubMed: 16374874]
5. Jacobsohn GM, Siegel ET, Jacobsohn MK. *J Clin Endocrinol Metab.* 1975; 40:177. [PubMed: 163969]
6. Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA. *Pharmacol Rev.* 2006; 58:773. [PubMed: 17132854]
7. Hammes SR, Levin ER. *Endo Rev.* 2007; 28:726.
8. Prossnitz ER, Maggiolini M. *Mol Cell Endocrinol.* 2009; 308:32. [PubMed: 19464786]
9. Olde B, Leeb-Lundberg LMF. *Trends Endocrinol Metab.* 2009; 20:409. [PubMed: 19734054]
10. Boulware MI, Mermelstein PG. *Steroids.* 2009; 74:608. [PubMed: 19070630]
11. Nilsson S, Makela S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M, Gustafsson JA. *Physiol Rev.* 2001; 81:1535. [PubMed: 11581496]
12. Ellmann S, Sticht H, Thiel F, Beckmann MW, Strick R, Strissel PL. *Cell Mol Life Sci.* 2009; 66:2405. [PubMed: 19333551]
13. Simpkins JW, Dykens JA. *Brain Res Rev.* 2008; 57:421. [PubMed: 17512984]
14. Wiese TE, Polin LA, Palomino E, Brooks SC. *J Med Chem.* 1997; 40:3659. [PubMed: 9357533]
15. Toran-Allerand CD, Tinnikov AA, Singh RJ, Nethrapalli IS. *Endocrinology.* 2005; 146:3843. [PubMed: 15947006]
16. Commodari F, Sclavos G, Ibrahim S, Khiat A, Boulanger Y. *Magn Reson Chem.* 2005; 43:444. [PubMed: 15809981]
17. Makriyannis A, Fesik S. *J Med Chem.* 1983; 26:463. [PubMed: 6834378]
18. Mavromoustakos T, Yang DP, Makriyannis A. *Biochim Biophys Acta.* 1994; 1194:69. [PubMed: 8075143]
19. Debrauwer L, Rathahao E, Jouanin I, Paris A, Clodic G, Molines H, Convert O, Fournier F, Tabet JC. *J Am Soc Mass Spectrom.* 2003; 14:364. [PubMed: 12686483]
20. Mersh JD, Sanders JKM. *Org Magn Reson.* 1982; 18:122.
21. Szántay C Jr. *Bull Magn Reson.* 1992; 14:112.
22. Busetta B, Hospital M. *C R Acad Sci Paris, Ser C.* 1969; 268:1300.
23. Busetta B, Barrans Y, Precigoux G, Hospital M. *Act Cryst B.* 1976; 32:1290.
24. Palomino E, Heeg MJ, Horwitz JP, Brooks SC. *J Steroid Biochem.* 1990; 35:219. [PubMed: 2308337]
25. Wiese TE, Brooks SC. *J Steroid Biochem Mol Biol.* 1994; 50:61. [PubMed: 8049135]
26. Lamminmaki U, Kankare JA. *J Biol Chem.* 2001; 276:36687. [PubMed: 11451948]

## Abbreviations


<b>COSY</b>	correlation spectroscopy
<b>E2</b>	17 $\beta$ -estradiol
<b>HSQC</b>	heteronuclear single quantum coherence
<b>NMR</b>	nuclear magnetic resonance
<b>NOE</b>	nuclear Overhauser effect
<b>NOESY</b>	nuclear Overhauser enhancement spectroscopy




**Figure 1.**  
The hormone 17 $\beta$ -estradiol (E2) and the isomeric antiestrogen 17 $\alpha$ -estradiol.



**Figure 2.**  
 $^1\text{H}$ - $^{13}\text{C}$  HSQC spectra of  $17\beta$ -estradiol (E2, left) and  $17\alpha$ -estradiol (right).




**Figure 3.** <sup>1</sup>H NMR of E2 (a) and E2-6β-*d* (b) in DMSO-*d*<sub>6</sub> solution. (a) The benzylic C-6 protons of E2 appeared as an ABXY pattern with the H<sub>6β</sub> (*ddd*) downfield of the H<sub>6α</sub> (*ddd*). (b) The deuterated analog, which contained approximately 10% non-deuterated E2, appeared as a broadened doublet with a 0.03 ppm upfield shift due to the isotope effect.



**Figure 4.**  
NOESY spectra of 17 $\beta$ -estradiol (E2, left) and 17 $\alpha$ -estradiol (right).





**Figure 5.** (a) The 20 low-energy conformers of 17β-estradiol (E2). (b) The 20 low-energy conformers of 17α-estradiol. (c) The unsaturated B-ring half-chair showing trans coplanar diaxial orientations for H<sub>6β</sub> with H<sub>7α</sub> and for H<sub>8</sub> with H<sub>9</sub>. (d) The C-ring chair with trans coplanar diaxial orientations for H<sub>11β</sub> with H<sub>9</sub> and H<sub>12α</sub> as well as for H<sub>8</sub> with H<sub>9</sub> and H<sub>14</sub>. (e) The D-ring for 17β-estradiol (E2). (f) The D-ring for 17α-estradiol.

**17 $\beta$ -Estradiol (E2)**

**Table 1**

Position	Chemical Shift (ppm)		<sup>1</sup> H- <sup>1</sup> H NOEs*
	$\delta_H$	$\delta_C$	
1	7.00	126.0	2(m); 9 (w); 11 $\beta$ (w)
2	6.47	112.7	1(m)
3	—	154.8	
4	6.39	114.9	6 $\alpha$ (m); 6 $\beta$ (w)
5	—	137.1	
6 $\alpha$	2.65	29.1	4(m); 7 $\alpha$ (w)
6 $\beta$	2.68		4(w); 7 $\beta$ (w); 8(w)
7 $\alpha$	1.19	26.9	6 $\alpha$ (w); 7 $\beta$ (s); 9(m)
7 $\beta$	1.74		6 $\beta$ (w); 7 $\alpha$ (s); 8(m)
8	1.24	38.7	7 $\beta$ (m); 18(m)
9	2.03	43.5	7 $\alpha$ (m); 11 $\alpha$ (w); 14(w)
10	—	130.4	
11 $\alpha$	2.19	26.0	9(w); 11 $\beta$ (s); 12 $\alpha$ (w)
11 $\beta$	1.27		11 $\alpha$ (s); 18(m)
12 $\alpha$	1.13	36.5	11 $\alpha$ (w); 12 $\beta$ (s); 14(w); 17(w)
12 $\beta$	1.80		12 $\alpha$ (s); 18(w)
13	—	42.8	
14	1.07	49.5	9(w); 12 $\alpha$ (w); 15 $\alpha$ (m)
15 $\alpha$	1.55	22.7	14(m); 15 $\beta$ (s); 16 $\alpha$ (w); 16 $\beta$ (w)
15 $\beta$	1.21		15 $\alpha$ (s); 16 $\alpha$ (w); 18(m)
16 $\alpha$	1.85	29.8	15 $\alpha$ (w); 15 $\beta$ (w); 16 $\beta$ (s); 17(m)
16 $\beta$	1.34		15 $\alpha$ (w); 16 $\alpha$ (s); 17(w); 18(w)
17	3.48	80.0	12 $\alpha$ (w); 16 $\alpha$ (m); 16 $\beta$ (w)
18	0.63	11.2	8(m); 11 $\beta$ (m); 12 $\beta$ (w); 15 $\beta$ (m); 16 $\beta$ (w)



\* NOE intensities were categorized as “strong” (s), “medium” (m) and “weak” (w), and were converted into upper limit distance constraints of 2.7, 3.5, and 5.0 Å in the molecular dynamics calculations, respectively.

**17 $\alpha$ -Estradiol****Table 2**

Position	Chemical Shift (ppm)		<sup>1</sup> H- <sup>1</sup> H NOEs*
	$\delta_H$	$\delta_C$	
1	7.02	126.0	2(m); 9(w); 11 $\beta$ (w)
2	6.46	112.6	1(m)
3	—	154.8	
4	6.39	114.8	6 $\alpha$ (m); 6 $\beta$ (w)
5	—	137.1	
6 $\alpha$	2.65	29.2	4(m); 7 $\alpha$ (w)
6 $\beta$	2.68		4(w); 7 $\beta$ (w); 8(w)
7 $\alpha$	1.26	27.8	6 $\alpha$ (w); 7 $\beta$ (s); 9(m)
7 $\beta$	1.78		6 $\beta$ (w); 7 $\alpha$ (s); 8(m)
8	1.22	38.8	7 $\beta$ (m); 18(m)
9	2.02	43.3	7 $\alpha$ (m); 11 $\alpha$ (w); 12 $\alpha$ (w); 14(w)
10	—	130.4	
11 $\alpha$	2.23	26.0	9(w); 11 $\beta$ (s); 12 $\alpha$ (w)
11 $\beta$	1.29		11 $\alpha$ (s); 18(m)
12 $\alpha$	1.71	31.4	9(w); 11 $\alpha$ (w); 12 $\beta$ (s); 14(m)
12 $\beta$	1.40		12 $\alpha$ (s); 17(w); 18(w)
13	—	45.0	
14	1.51	47.2	9(w); 12 $\alpha$ (m); 15 $\alpha$ (m)
15 $\alpha$	1.67	23.8	14(m); 15 $\beta$ (s); 16 $\alpha$ (w); 16 $\beta$ (w)
15 $\beta$	1.12		15 $\alpha$ (s); 16 $\alpha$ (w); 18(w)
16 $\alpha$	1.34	32.0	15 $\alpha$ (w); 15 $\beta$ (w); 16 $\beta$ (s); 17(w)
16 $\beta$	2.01		15 $\alpha$ (w); 16 $\alpha$ (s); 17(m); 18(w)
17	3.54	77.9	12 $\beta$ (w); 16 $\alpha$ (w); 16 $\beta$ (m); 18(m)
18	0.58	16.9	8(m); 11 $\beta$ (m); 12 $\beta$ (w); 15 $\beta$ (w); 16 $\beta$ (w); 17(m)

\* NOE intensities were categorized as “strong” (s), “medium” (m) and “weak” (w), and were converted into upper limit distance constraints of 2.7, 3.5, and 5.0 Å in the molecular dynamics calculations, respectively.

**Table 3**  
**Observed coupling constants for 17 $\beta$ - and 17 $\alpha$ -estradiol**

 17 $\beta$ -estradiol (E2)		<i>J</i> (Hz)	 17 $\alpha$ -estradiol		<i>J</i> (Hz)
$J_{1,2}$	8.5	$J_{1,2}$	8.4		
$J_{2,4}$	2.7	$J_{2,4}$	2.6		
$J_{6\alpha,6\beta}$	17.1	$J_{6\alpha,6\beta}$	17.1		
$J_{6\alpha,7\alpha}$	6.3	$J_{6\alpha,7\alpha}$	6.3		
$J_{6\alpha,7\beta}$	2.4	$J_{6\alpha,7\beta}$	2.4		
$J_{6\beta,7\alpha}$	11.6	$J_{6\beta,7\alpha}$	11.3		
$J_{6\beta,7\beta}$	6.1	$J_{6\beta,7\beta}$	6.2		
$J_{7\alpha,7\beta}$	12.3	$J_{7\alpha,7\beta}$	12.6		
$J_{7\alpha,8}$	12.0	$J_{7\alpha,8}$	12.0		
$J_{7\beta,8}$	2.3	$J_{7\beta,8}$	2.5		
$J_{8,9}$	11.2	$J_{8,9}$	11.2		
$J_{8,14}$	12.4	$J_{8,14}$	12.2		
$J_{9,11\alpha}$	4.3	$J_{9,11\alpha}$	4.3		
$J_{9,11\beta}$	11.2	$J_{9,11\beta}$	11.0		
$J_{11\alpha,11\beta}$	13.5	$J_{11\alpha,11\beta}$	13.4		
$J_{11\alpha,12\alpha}$	4.1	$J_{11\alpha,12\alpha}$	4.3		
$J_{11\alpha,12\beta}$	2.9	$J_{11\alpha,12\beta}$	2.7		
$J_{11\beta,12\alpha}$	12.8	$J_{11\beta,12\alpha}$	13.2		
$J_{11\beta,12\beta}$	3.8	$J_{11\beta,12\beta}$	4.0		
$J_{12\alpha,12\beta}$	12.7	$J_{12\alpha,12\beta}$	13.0		
$J_{14,15\alpha}$	7.4	$J_{14,15\alpha}$	7.4		
$J_{14,15\beta}$	10.8	$J_{14,15\beta}$	10.8		
$J_{15\alpha,15\beta}$	12.1	$J_{15\alpha,15\beta}$	12.1		
$J_{15\alpha,16\alpha}$	9.4	$J_{15\alpha,16\alpha}$	9.5		
$J_{15\alpha,16\beta}$	3.4	$J_{15\alpha,16\beta}$	2.9		
$J_{15\beta,16\alpha}$	5.8	$J_{15\beta,16\alpha}$	6.6		
$J_{15\beta,16\beta}$	11.5	$J_{15\beta,16\beta}$	12.2		
$J_{16\alpha,16\beta}$	13.4	$J_{16\alpha,16\beta}$	14.3		
$J_{16\alpha,17\alpha}$	8.9	$J_{16\alpha,17\beta}$	0.0		
$J_{16\beta,17\alpha}$	8.4	$J_{16\beta,17\beta}$	5.8		